nach oben

Clinical Pharmacokinetics

Erschienen in:

01.01.2006 | Commentary

‘Hedged’ Prescribing for Partially Compliant Patients

How Accurate Are Available Scaling Methods?

verfasst von: John Urquhart, Bernard Vrijens

Erschienen in: Clinical Pharmacokinetics | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Excerpt

The term ‘hedge’ has multiple meanings; its use here is analogous to its meaning in financial markets, i.e. ‘to protect oneself from losing or failing by a counterbalancing action’.[1] The paper by Blesius et al.[2] strives to achieve a therapeutically useful degree of ‘counterbalancing action’ in the prescribing of oral anticoagulants by switching between either of two available drugs and/or between once- and twice-daily dosing. Their approach deserves attention and consideration for extension into other fields of ambulatory pharmacotherapy as a risk-management tool. …

The use of trade names is for product identification purposes only and does not imply endorsement.

Merriam-Webster’s Collegiate Dictionary, 10th ed. Springfield (MA): Merriam-Webster, Inc., 2001

Blesius A, Chabaud S, Cucherat M, et al. Compliance-guided therapy: a new insight into the potential role of clinical pharmacologists. Clin Pharmacokinet 2005; 45(1): 95–104CrossRef

Urquhart J. Variable compliance and persistence with prescribed drug dosing regimens: implications for benefits, risks, and economics of pharmacotherapy. In: Strom B, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley, 2005: 767–89

Potter LS. Oral contraceptive compliance and its role in the effectiveness of the method. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991: 195–207

Guillebaud J. Any questions. BMJ 1993; 307: 617

“What to do if you miss pills”? In: Physicians’ desk reference. 59th ed. Montvale (NJ): Medical Economics Co.: 2541

Ten great public health achievements US, 1900–99: family planning. MMWR 1999; 48: 1073-80

Urquhart J. The odds of the three nons when an aptly prescribed medicine isn’t working: noncompliance, nonabsorption, non-response. Brit J Clin Pharmacol 2002; 54: 212–20CrossRef

Urquhart J. Controlled drug delivery: pharmacologic and therapeutic aspects. J Internal Med 2000; 248: 357–76PubMedCrossRef

10.

Vrijens B, Gross R, Urquhart J. The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses. Basic Clin Pharmacol Toxicol 2005; 96: 225–7PubMedCrossRef

11.

Vrijens B, Comte L, Tousset E, et al. Once-daily versus twice-daily regimens: which is best for HIV-infected patients [abstract no. 3; poster no. 1.3]. 6th International Workshop on Clinical Pharmacology of HIV Therapy. 2005 Apr 28–30. Quebec City (QC)

12.

Levy G. A pharmacokinetic perspective on medicament non-compliance. Clin Pharmacol Ther 1993; 54: 242–4PubMedCrossRef

13.

Kruse W, Rampmaier J, Ullrich G, et al. Patterns of drug compliance with medication to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 1994; 32: 452–7PubMed

Titel: ‘Hedged’ Prescribing for Partially Compliant Patients
How Accurate Are Available Scaling Methods?
verfasst von: John Urquhart
Bernard Vrijens
Publikationsdatum: 01.01.2006
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 1/2006
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200645010-00008

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2006

Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Ximelagatran in Young Healthy Japanese Men

Population Pharmacokinetics of Tacrolimus in Whole Blood and Plasma in Asian Liver Transplant Patients

Mass Balance Studies, with a Focus on Anticancer Drugs

Comparable Pharmacokinetics and Pharmacodynamics of Melagatran in Japanese and Caucasian Volunteers after Oral Administration of the Direct Thrombin Inhibitor Ximelagatran

Compliance-Guided Therapy

Significance of the Minor Cytochrome P450 3A Isoforms